Back to search results
NCT07424508

Movement State-dependent Adaptive DBS for PD

Enrolling by Invitation
NAAges 21–75InterventionalTreatment
Doris Wang, MD, PhD
~6 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Summit RC+S

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scores
Measured over after each 7 day block
+8 more outcomes measured

Conditions

Parkinson's Disease (PD)

Explore related trials

Parkinson Disease

NCT07424508

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UCSF

    San Francisco, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Doris Wang, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to give informed consent for the study
Subjects implanted with Summit RC+S investigational DBS system.
Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA)
Signed informed consent
Age 21-75
Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater
Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist.
UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management
Patients with gait impairments: slowed gait, shuffling steps, postural instability, or freezing of gait off medication.

Exclusion

Inability to comply with study procedures
Patients who cannot walk (wheelchair bound)

What this trial measures

  • Change in Mini Balance Evaluation Systems Test (Mini-BESTest) Scoresafter each 7 day block

    Change in Mini-BESTest scores, which is a clinical balance evaluations systems test. The score range is 0-2 with higher scores indicating higher levels of physical functioning.

  • Change in Gait14 day long-term testing period

    Change in gait measurements using the wearable devices (i.e., ankle wristband Rover and STAT-ON Holter)

  • Change in Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scoresafter each 7 day block

    Change in MDS-UPDRS III score. The scale consists of 18 items that are each scored 0 to 3, making the total score out of 72 points, with higher scores indicating higher impairment.

  • Change in Stride Length14 day long-term testing period

    Change in stride length measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride length measured in meters.

  • Change in Stride Time14 day long-term testing period

    Change in stride time measured by Rover (a gait measurement device) and STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS). Stride time measured in seconds.

  • Change in Double Support Time14 day long-term testing period

    Change in stride time measured by Rover (a gait measurement device). Each gait cycle consists of two phases, where both feet are in contact with the ground, called Double Support. Double support time will be measured in seconds (i.e. amount of time both feet are in contact with the ground).

  • Change in number of freezes14 day long-term testing period

    Change in number of freezes measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).

  • Change in number of falls14 day long-term testing period

    Change in number of falls measured by STAT-ON (a Parkinson's disease motor symptoms measurement device) with closed-loop compared to open-loop deep brain stimulation (DBS).

  • Change in Activities-Specific Balance Confidence (ABC) Scaleonce per day during 14 day long-term testing period

    Change in ABC Scale, which collects measures of confidence in performing various ambulatory activities without falling or experiencing a sense of unsteadiness. The score range is 0-100 with higher scores indicating higher levels of physical functioning.